PL1643983T3 - Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy - Google Patents

Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy

Info

Publication number: PL1643983T3
Authority: PL; Poland
Prior art keywords: sphingosine; methods; vascular endothelial; vascular permeability; apoptosis
Prior art date: 2003-06-24

Application number

PL04776717T

Other languages

English (en)

Inventor

Timothy Hla

Teresa Sanchez

Ji-Hye Paik

Kevin P Claffey

Original Assignee

Univ Connecticut

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-24

Filing date

2004-06-18

Publication date

2010-10-29

2004-06-18 Application filed by Univ Connecticut filed Critical Univ Connecticut

2010-10-29 Publication of PL1643983T3 publication Critical patent/PL1643983T3/pl

Links

230000008728 vascular permeability Effects 0.000 title abstract 3
238000000034 method Methods 0.000 title abstract 2
230000006907 apoptotic process Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 abstract 4
108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 abstract 4
239000000018 receptor agonist Substances 0.000 abstract 3
229940044601 receptor agonist Drugs 0.000 abstract 3
210000004204 blood vessel Anatomy 0.000 abstract 2
230000004528 endothelial cell apoptotic process Effects 0.000 abstract 2
230000003511 endothelial effect Effects 0.000 abstract 2
230000002792 vascular Effects 0.000 abstract 2
210000003556 vascular endothelial cell Anatomy 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 1
102100027662 Sphingosine kinase 2 Human genes 0.000 abstract 1
101710156532 Sphingosine kinase 2 Proteins 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 abstract 1
229960000556 fingolimod Drugs 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Neurology (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Cardiology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PL04776717T 2003-06-24 2004-06-18 Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy PL1643983T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US48223403P	2003-06-24	2003-06-24
PCT/US2004/019420 WO2005002559A2 (en)	2003-06-24	2004-06-18	Methods of inhibiting vascular permeability and apoptosis
EP04776717A EP1643983B1 (en)	2003-06-24	2004-06-18	Methods of inhibiting vascular permeability and apoptosis

Publications (1)

Publication Number	Publication Date
PL1643983T3 true PL1643983T3 (pl)	2010-10-29

Family

ID=33563841

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04776717T PL1643983T3 (pl)	2003-06-24	2004-06-18	Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy

Country Status (14)

Country	Link
US (3)	US7838562B2 (pl)
EP (1)	EP1643983B1 (pl)
JP (2)	JP2007523858A (pl)
CN (2)	CN100431534C (pl)
AT (1)	ATE466572T1 (pl)
AU (1)	AU2004253473B2 (pl)
BR (1)	BRPI0411831A (pl)
CA (3)	CA2778126A1 (pl)
DE (1)	DE602004027045D1 (pl)
ES (1)	ES2342396T3 (pl)
MX (1)	MXPA05014216A (pl)
PL (1)	PL1643983T3 (pl)
PT (1)	PT1643983E (pl)
WO (1)	WO2005002559A2 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003233119A1 (en)	2002-05-08	2003-11-11	Neuronova Ab	Modulation of neural stem cells with s1p or lpa receptor agonists
GB0329498D0 (en) *	2003-12-19	2004-01-28	Novartis Ag	Organic compounds
EP1845971A4 (en) *	2005-01-21	2009-12-30	Medvet Science Pty Ltd	METHOD FOR THE TREATMENT OF CELL DAMAGE
KR100773765B1 (ko)	2005-11-24	2007-11-12	재단법인서울대학교산학협력재단	개선된 스핑고신 유사체의 제조 방법
HUE046441T2 (hu) *	2006-09-26	2020-02-28	Novartis Ag	S1P modulátort tartalmazó gyógyászati készítmények
EP1905434A1 (en) *	2006-09-26	2008-04-02	Novartis AG	Organic compounds comprising an S1P receptor agonist and their therapeutic use
PL2083811T3 (pl)	2006-11-22	2017-05-31	Clinical Research Associates, Llc	Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
EP3733161A1 (en)	2007-10-12	2020-11-04	Novartis AG	Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
CN102464590B (zh) *	2010-11-18	2013-10-23	中国科学院上海药物研究所	一类免疫调节剂及其制备方法和用途
ES2388273B1 (es) *	2011-03-16	2013-10-01	Consejo Superior De Investigaciones Científicas (Csic)	Uso de inhibidores de receptores de s1p para el tratamiento de la estenosis aórtica calcificada
EP2831072B1 (en)	2012-03-26	2017-04-19	Arroyo BioSciences L.L.C.	Novel sphingosine 1-phosphate receptor antagonists
WO2013181488A2 (en) *	2012-06-01	2013-12-05	The Ohio State University Research Foundation	Inhibition of leukemic stem cells by pp2a activating agents
US20150258168A1 (en) *	2012-09-12	2015-09-17	Oklahoma Medical Research Foundation	Modulation of podoplanin mediated platelet activation
WO2014175287A1 (ja) *	2013-04-26	2014-10-30	国立大学法人京都大学	脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
WO2016035769A1 (ja) *	2014-09-01	2016-03-10	パスロジ株式会社	ユーザ認証方法及びこれを実現するためのシステム
WO2016115092A1 (en) *	2015-01-12	2016-07-21	La Jolla Institute For Allergy And Immunology	Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
US10111841B2 (en)	2015-06-19	2018-10-30	University Of South Florida	Stabilization of alcohol intoxication-induced cardiovascular instability
CN105395530A (zh) *	2015-11-27	2016-03-16	天津医科大学总医院	芬戈莫德的新用途
CN105640928A (zh) *	2016-02-26	2016-06-08	南京医科大学	Fty720在制备预防与治疗缺血性脑卒药物中的应用
CN108939074B (zh) *	2017-05-22	2022-06-10	北京蔚蓝之源医药科技有限公司	治疗再生障碍性贫血的方法和药物组合物
CN111683682A (zh) *	2018-02-02	2020-09-18	国立大学法人京都大学	用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
EP3677259A1 (en) *	2019-01-07	2020-07-08	Mosaiques Diagnostics And Therapeutics AG	Use of arachidonyl trifluoromethyl ketone
US12472171B2 (en) *	2020-08-19	2025-11-18	Biogen Ma Inc.	Methods for treating hypercholesterolemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU7370594A (en) *	1993-07-23	1995-02-20	Lxr Biotechnology Inc.	Methods of treating apoptosis and associated conditions
US5948820A (en) *	1994-08-22	1999-09-07	Yoshitomi Pharmaceutical Industries, Ltd.	Benzene compound and pharmaceutical use thereof
US6476004B1 (en) *	1996-07-18	2002-11-05	Mitsubishi Pharma Corporation	Pharmaceutical composition
US6043224A (en) *	1996-09-05	2000-03-28	The Massachusetts Institute Of Technology	Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
GB9624038D0 (en) *	1996-11-19	1997-01-08	Sandoz Ltd	Organic compounds
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
JPH11246434A (ja) *	1998-02-25	1999-09-14	Sumitomo Pharmaceut Co Ltd	ｂａｘの低下及び／又はｂｃｌ−２の増加誘導剤
US6423508B1 (en) *	1998-03-09	2002-07-23	Smithkline Beecham Corporation	Polynucleotide sequences of human EDG-1c
JP4627356B2 (ja) *	1999-06-30	2011-02-09	昭松森	ウイルス性心筋炎の予防または治療薬剤
NZ526622A (en) *	2000-12-11	2006-07-28	Amgen Sf Llc	CXCR3 antagonists
US6471980B2 (en) *	2000-12-22	2002-10-29	Avantec Vascular Corporation	Intravascular delivery of mycophenolic acid
WO2003014727A1 (fr) *	2001-08-08	2003-02-20	Chugai Seiyaku Kabushiki Kaisha	Medicaments pour maladies cardiaque
WO2003061567A2 (en)	2002-01-18	2003-07-31	Merck & Co., Inc.	Selective s1p1/edg1 receptor agonists
US20040058894A1 (en) *	2002-01-18	2004-03-25	Doherty George A.	Selective S1P1/Edg1 receptor agonists
GB0217152D0 (en)	2002-07-24	2002-09-04	Novartis Ag	Organic compounds

2004
- 2004-06-18 PL PL04776717T patent/PL1643983T3/pl unknown
- 2004-06-18 EP EP04776717A patent/EP1643983B1/en not_active Expired - Lifetime
- 2004-06-18 CN CNB2004800175481A patent/CN100431534C/zh not_active Expired - Fee Related
- 2004-06-18 CA CA2778126A patent/CA2778126A1/en not_active Abandoned
- 2004-06-18 ES ES04776717T patent/ES2342396T3/es not_active Expired - Lifetime
- 2004-06-18 CN CN200810212366A patent/CN101518524A/zh active Pending
- 2004-06-18 CA CA2529318A patent/CA2529318C/en not_active Expired - Fee Related
- 2004-06-18 MX MXPA05014216A patent/MXPA05014216A/es active IP Right Grant
- 2004-06-18 AT AT04776717T patent/ATE466572T1/de active
- 2004-06-18 BR BRPI0411831-6A patent/BRPI0411831A/pt not_active IP Right Cessation
- 2004-06-18 DE DE602004027045T patent/DE602004027045D1/de not_active Expired - Lifetime
- 2004-06-18 CA CA2778309A patent/CA2778309C/en not_active Expired - Fee Related
- 2004-06-18 WO PCT/US2004/019420 patent/WO2005002559A2/en not_active Ceased
- 2004-06-18 US US10/562,305 patent/US7838562B2/en not_active Expired - Fee Related
- 2004-06-18 PT PT04776717T patent/PT1643983E/pt unknown
- 2004-06-18 JP JP2006517361A patent/JP2007523858A/ja not_active Withdrawn
- 2004-06-18 AU AU2004253473A patent/AU2004253473B2/en not_active Ceased
2010
- 2010-09-30 US US12/894,783 patent/US9101575B2/en not_active Expired - Fee Related
2014
- 2014-01-07 JP JP2014001034A patent/JP2014088421A/ja active Pending
2015
- 2015-06-18 US US14/743,352 patent/US20150283154A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080039530A1 (en)	2008-02-14
US9101575B2 (en)	2015-08-11
DE602004027045D1 (de)	2010-06-17
US20150283154A1 (en)	2015-10-08
CN100431534C (zh)	2008-11-12
EP1643983A2 (en)	2006-04-12
ATE466572T1 (de)	2010-05-15
CN1826104A (zh)	2006-08-30
AU2004253473B2 (en)	2010-03-04
AU2004253473A1 (en)	2005-01-13
CA2778309C (en)	2014-12-02
PT1643983E (pt)	2010-06-18
EP1643983B1 (en)	2010-05-05
CA2778309A1 (en)	2005-01-13
CA2778126A1 (en)	2005-01-13
CA2529318C (en)	2013-09-17
BRPI0411831A (pt)	2006-08-08
US20110015159A1 (en)	2011-01-20
WO2005002559A2 (en)	2005-01-13
ES2342396T3 (es)	2010-07-06
WO2005002559A3 (en)	2005-04-14
JP2014088421A (ja)	2014-05-15
JP2007523858A (ja)	2007-08-23
MXPA05014216A (es)	2006-03-13
CA2529318A1 (en)	2005-01-13
US7838562B2 (en)	2010-11-23
CN101518524A (zh)	2009-09-02

Publication	Publication Date	Title
PL1643983T3 (pl)	2010-10-29	Sposoby hamowania przepuszczalności naczyń krwionośnych i apoptozy
UA98629C2 (ru)	2012-06-11	Соединения и способ модуляции киназ
WO2007136790A3 (en)	2008-11-27	Intracellular kinase inhibitors
TW200634006A (en)	2006-10-01	Tetrahydroquinoline analogues as muscarinic agonists
NO20083002L (no)	2008-08-14	Fremgangsmate for anvendelse av CD40-bindende forbindelser
MX2009006345A (es)	2009-06-23	Compuestos utiles como inhibidores de proteina cinasa.
MX2009006688A (es)	2009-06-30	Compuestos y metodos para modulacion de cinasas, e indicaciones para ello.
MXPA05012678A (es)	2006-02-22	Forma cristalina del agonista del receptor adrenergico beta2.
WO2008028141A3 (en)	2008-04-10	Raf inhibitor compounds and methods of use thereof
TW200626068A (en)	2006-08-01	Active compounds for seed treatment
WO2008060907A3 (en)	2009-06-11	Pyrrolo-pyridine kinase inhibitors
WO2005086860A3 (en)	2009-04-02	Methods for generating insulin-producing cells
MX2009007023A (es)	2009-09-09	Agonistas de receptores heterociclicos para el tratamiento de diabetes y trastornos metabolicos.
WO2009120919A3 (en)	2010-11-04	Fenofibrate dosage forms
WO2007092190A3 (en)	2007-11-29	Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
WO2008057930A3 (en)	2008-06-26	Methods of treating neuropathic pain with retinoic acid receptor agonists
EP2510925A3 (en)	2013-01-30	Small-Molecule modulators of TRP-P8 activity
WO2007100640A3 (en)	2008-07-31	Growth hormone receptor antagonist cancer treatment
WO2006073890A3 (en)	2007-01-25	Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
WO2006007378A3 (en)	2006-05-04	Pyrrolotriazine kinase inhibitors
RU2014124430A (ru)	2015-12-27	Средство для лечения фиброза кишечника
WO2007109288A3 (en)	2008-04-03	Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
TW200833688A (en)	2008-08-16	Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
NZ596104A (en)	2014-01-31	7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
MX2009005231A (es)	2009-06-19	Composiciones utiles como inhibidores de proteina cinasa.